First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

Scottish Gynecological Cancers Trials Group; Roshan Agarwal; Charles Gourley; Timothy J Perren; Nicholas Reed; David E Parkin; Karen Carty; Gordon J S Rustin; Hani Gabra; Jim Paul; Martin E Gore; Stanley B Kaye

doi:10.1016/j.ejca.2010.03.006

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

Scottish Gynecological Cancers Trials Group, Roshan Agarwal, Charles Gourley, Timothy J Perren, Nicholas Reed, David E Parkin, Karen Carty, Gordon J S Rustin, Hani Gabra, Jim Paul, Martin E Gore, Stanley B Kaye

Research output: Contribution to journal › Article › peer-review

Abstract

We have conducted a series of four feasibility studies in stage Ic-IV ovarian cancer exploring six sequential first-line schedules with the same entry criteria in a total of 339 patients. Here we present the results of the sixth study, and an analysis of the overall series.

Original language	English
Pages (from-to)	2020-6
Number of pages	7
Journal	European Journal of Cancer
Volume	46
Issue number	11
DOIs	https://doi.org/10.1016/j.ejca.2010.03.006
Publication status	Published - 2010

Keywords

Carboplatin
Paclitaxel
Gemcitabine
Sequential therapy
Ovarian cancer

Access to Document

10.1016/j.ejca.2010.03.006

Cite this

Scottish Gynecological Cancers Trials Group, Agarwal, R., Gourley, C., Perren, T. J., Reed, N., Parkin, D. E., Carty, K., Rustin, G. J. S., Gabra, H., Paul, J., Gore, M. E., & Kaye, S. B. (2010). First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. European Journal of Cancer, 46(11), 2020-6. https://doi.org/10.1016/j.ejca.2010.03.006

@article{155dad270c9447339d1fab366b6dd72b,

title = "First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series",

abstract = "We have conducted a series of four feasibility studies in stage Ic-IV ovarian cancer exploring six sequential first-line schedules with the same entry criteria in a total of 339 patients. Here we present the results of the sixth study, and an analysis of the overall series.",

keywords = "Carboplatin, Paclitaxel, Gemcitabine, Sequential therapy, Ovarian cancer",

author = "{Scottish Gynecological Cancers Trials Group} and Roshan Agarwal and Charles Gourley and Perren, {Timothy J} and Nicholas Reed and Parkin, {David E} and Karen Carty and Rustin, {Gordon J S} and Hani Gabra and Jim Paul and Gore, {Martin E} and Kaye, {Stanley B}",

year = "2010",

doi = "10.1016/j.ejca.2010.03.006",

language = "English",

volume = "46",

pages = "2020--6",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

number = "11",

}

Scottish Gynecological Cancers Trials Group, Agarwal, R, Gourley, C, Perren, TJ, Reed, N, Parkin, DE, Carty, K, Rustin, GJS, Gabra, H, Paul, J, Gore, ME & Kaye, SB 2010, 'First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series', European Journal of Cancer, vol. 46, no. 11, pp. 2020-6. https://doi.org/10.1016/j.ejca.2010.03.006

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) : a feasibility study and comparative analysis of the SCOTROC series. / Scottish Gynecological Cancers Trials Group; Agarwal, Roshan; Gourley, Charles et al.

In: European Journal of Cancer, Vol. 46, No. 11, 2010, p. 2020-6.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5)

T2 - a feasibility study and comparative analysis of the SCOTROC series

AU - Scottish Gynecological Cancers Trials Group

AU - Agarwal, Roshan

AU - Gourley, Charles

AU - Perren, Timothy J

AU - Reed, Nicholas

AU - Parkin, David E

AU - Carty, Karen

AU - Rustin, Gordon J S

AU - Gabra, Hani

AU - Paul, Jim

AU - Gore, Martin E

AU - Kaye, Stanley B

PY - 2010

Y1 - 2010

N2 - We have conducted a series of four feasibility studies in stage Ic-IV ovarian cancer exploring six sequential first-line schedules with the same entry criteria in a total of 339 patients. Here we present the results of the sixth study, and an analysis of the overall series.

AB - We have conducted a series of four feasibility studies in stage Ic-IV ovarian cancer exploring six sequential first-line schedules with the same entry criteria in a total of 339 patients. Here we present the results of the sixth study, and an analysis of the overall series.

KW - Carboplatin

KW - Paclitaxel

KW - Gemcitabine

KW - Sequential therapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=77954212827&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2010.03.006

DO - 10.1016/j.ejca.2010.03.006

M3 - Article

C2 - 20395128

VL - 46

SP - 2020

EP - 2026

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this